Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen

References

• Hammond C B, Soules M R. Endocine aspects of the endometrium. Gynecology and Obstetrics, H J Buchsbaum, J J Sciarra. Harper & Row, Philadelphia 1984; 14: 1–5
   Google Scholar
• Daniel Y, Inbar M, Bar-Am A, et al. The effects of tamoxifen treatment on the endometrium. Fertil Steril 1996; 65: 1083–1089
   PubMed Web of Science ®Google Scholar
• Nayfield S G, Karp J E, Ford L G, Dorr F A, Kramer B S. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83: 1450–1459
   PubMed Web of Science ®Google Scholar
• Baum M. the Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Br J Cancer 1988; 57: 608–611
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319: 1681–1692
   PubMed Web of Science ®Google Scholar
• Gottardis M M, Robinson S P, Satyawaroop P G, Jordan V C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48: 812–815
   PubMed Web of Science ®Google Scholar
• Neven P. Local levonorgestrel to prevent tamoxifen-related endometrial lesions. Lancet 2000; 356: 1698–1699
   PubMed Web of Science ®Google Scholar
• Bergman L, Beelen M RL, Gallee M PW, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000; 356: 881–887
   PubMed Web of Science ®Google Scholar
• Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Safety 2000; 22: 1–11
   PubMed Web of Science ®Google Scholar
• Juneja M, Jose R, Kekre A N, Viswanathan F, Seshadri L. Tamoxifen-induced endometrial changes in postmenopausal women with breast carcinoma. Int J Gynaecol Obstet 2002; 76: 279–284
   PubMed Web of Science ®Google Scholar
• Gardner F JE, Konje J C, Abrams K R, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356: 1711–1717
   PubMed Web of Science ®Google Scholar
• Ballard P, Turnbull L, Richmond I, Tetlow R. The effect of a levonorgestrol intrauterine system on the endometrium of patients receiving long-term tamoxifen treatment for breast cancer. Br J Obstet Gynaecol 1998; 105(Suppl 17), abstr 299
   Google Scholar
• Speroff L. Amenorrhea. Clinical Gynecologic Endocrinology and Infertility6th edn, R H Glass, N G Kase, L Speroff. Williams & Wilkins, Baltimore 1996; 11: 421–486
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–1467
   PubMed Web of Science ®Google Scholar
• Van Leeuwen F E, Bernaadt J, Coebergh J W, Kiemeney L A, Gimbrere C H, Otter R. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448–452
   PubMed Web of Science ®Google Scholar
• Assikis V J, Neven P, Jordan V C, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996; 32A: 1464–1476
   PubMed Web of Science ®Google Scholar
• Sasco A J, Chaplain G, Amoros E, Saez S. Endometrial cancer following breast cancer; effect of tamoxifen and castration by radiotherapy. Epidemiology 1996; 7: 9–13
   PubMed Web of Science ®Google Scholar
• Bernstein L, Deapen D, Cerhan J R, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91: 1654–1662
   PubMed Web of Science ®Google Scholar
• Satyaswaroop P G, Zaino R J, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984; 44: 4006–4010
   PubMed Web of Science ®Google Scholar
• Martin L, Middleton E. Prolonged estrogenic and mitogenic activity of tamoxifen in ovariectomized mouse. J Endocrinol 1978; 78: 125–129
   PubMed Web of Science ®Google Scholar
• De Muylder X, Neven P, De Somer M, et al. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet 1991; 36: 127–130
   PubMed Web of Science ®Google Scholar
• Powles T J, Bourne T, Athanasiou S, et al. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer 1998; 78: 272–275
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Toivonen J, Luukkainen T. Therapeutic use of the LNG-IUS and counseling. Semin Reprod Med 2001; 19: 365–372
   PubMed Web of Science ®Google Scholar
• Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001; 19: 355–363
   PubMed Web of Science ®Google Scholar
• Jones R L, Critchley H O. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 2000; 15(Suppl 3)162–172
   PubMed Web of Science ®Google Scholar
• Raudoskoski T, Tapanainen J, Tomas E. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral estrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 2002; 109: 136–144
   Google Scholar
• Wollter-Svensson L O, Stadberg E, Anderson K, et al. Intrauterine administration of levonorgestrel in two low doses in HRT randomised clinical trial during one year; effects on lipid and lipoprotein metabolism. Maturitas 1995; 22: 199–205
   PubMed Web of Science ®Google Scholar